Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websitemedimmuneventures...
Twitter@MedImmune
Phone(301) 398-4624
Emailmedimmuneventures...
Employees
Founded1987
DescriptionVenture Capital

Funds

Offices

HQ
One MedImmune Way
Gaithersburg, MD, 20878
USA
Mountain View, USA
319 N Bernardo Ave
Mountain View, CA, 94043
USA

People

Managing Director
Managing Director
Managing Director
Vice President
Principal
Senior Associate
Senior Managing Director
Senior Managing Director
Administrative Assistant III

Tags

MedImmune Ventures

MedImmune Ventures is a wholly owned venture capital fund within the AstraZeneca/MedImmune group of companies. It was created in 2002 to leverage MedImmune’s expertise in discovering, developing and commercializing biotechnology products, as well as its financial resources, to transform new ideas in biotechnology into successful products and companies.

MedImmune Ventures invests in early- to late-stage, public or private biotechnology companies focused on discovering and developing human therapeutics. MedImmune Ventures primarily seeks to invest in areas of strategic interest to Astra Zeneca and MedImmune, including infectious diseases, cancer, inflammatory diseases, cardiovascular and metabolic disorders, pain and central nervous system disorders, and gastrointestinal disease. We are modality agnostic, investing in biologics, small molecules, and vaccines.

Recent Milestones

Investments

Company Date Round Size Participants
Catabasis Pharmaceuticals 11/2013Series B$32.4M5
G1 Therapeutics 10/2013Series A$12.5M3
Inotek Pharmaceuticals 9/2013Debt$7M6
Catabasis Pharmaceuticals 2/2013Venture Round$9M4
Applied Genetics Technologies Corporation 11/2012Series B$37.5M6
Ambit Biosciences 11/2012Venture Round$50M9
Coferon 7/2012Series B$12M3
Catabasis Pharmaceuticals 12/2011Series A$8M4
Inotek Pharmaceuticals 7/2011Series D$23.6M5
Ambit Biosciences 6/2011Series D$30M10
Corridor Pharmaceuticals 6/2010Series A$13M8
Catabasis Pharmaceuticals 4/2010Series A$39M4
VentiRx Pharmaceuticals 1/2010Series A$51.6M4
Virdante Pharmaceuticals 11/2009Series A$30M6
Corridor Pharmaceuticals 10/2009Series A$10.8M4
LigoCyte Pharmaceuticals 8/2009Series C$29.5M4
VaxInnate 6/2009Series D$30M7
Applied Genetics Technologies Corporation 6/2009Series C$11.8M3
NKT Therapeutics 3/2009Series A$8M2
Melinta 1/2009Private Equity$25M8
Hydra Biosciences 1/2009Series D$22M1
Corridor Pharmaceuticals 10/2008Angel$2.3M4
BrainCells 3/2008Series B$30M6
Sequoia Pharmaceuticals 1/2007Series C$35M5
VaxInnate 10/2006Series C$40M6
VLST Corporation 6/2006Series B$55M7
Avidia 5/2006Series C$43.8M7
Avidia 5/2005Series B$28.5M2
Applied Genetics Technologies Corporation 11/2003Series B$27M4

Videos

Sources

  1. Catabasis Pharmaceuticals Completes $32.4M Series B Financing (finsmes.com) [edit]
  2. G1 Therapeutics Raises $12.5M in Series A Financing (finsmes.com) [edit]
  3. Inotek Pharmaceuticals Raises $21 Million to Support Ongoing Clinical Development of Trabodenoson, a Novel Eye Drop for the Treatment of Glaucoma (inotekcorp.com) [edit]
  4. Catabasis raises $9M for PhII-ready drug development program (fiercebiotech.com) [edit]
  5. Applied Genetic Technologies Corporation Lands $37.5 Million in Venture Capital Funding (biospace.com) [edit]
  6. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia (phx.corporate-ir.net) [edit]
  7. Coferon, Inc. Announces $12 Million Series B Financing (marketwire.com) [edit]
  8. Catabasis Pharmaceuticals Announces $8 Million Series A Extension Financing (catabasispharma.com) [edit]
  9. SEC (sec.gov) [edit]
  10. AMBIT BIOSCIENCES COMPLETES $30 MILLION SERIES D-2 FINANCING (phx.corporate-ir.net) [edit]
  11. SEC (sec.gov) [edit]
  12. Catabasis lands $39M Series A for diabetes programs (fiercebiotech.com) [edit]
  13. VentiRx Pharma Extends Series A To $51.6M (fis.dowjones.com) [edit]
  14. Virdante Pharmaceuticals, Inc.: Series A $30M (onbiovc.com) [edit]
  15. Corridor Pharmaceuticals-Receives-$10,750,000 (venturedeal.com) [edit]
  16. SEC D/A (sec.gov) [edit]
  17. VaxInnate Corp., Series D $30M (onbiovc.com) [edit]
  18. Applied Genetic Technologies Corp.: Series C $11.8M (onbiovc.com) [edit]
  19. NKT Therapeutics launches with $8M (bizjournals.com) [edit]
  20. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing (rib-x.com) [edit]
  21. Hydra Biosciences Raises $22 Million in Series D Financing (reuters.com) [edit]
  22. Arginetix, Inc. Completes $2.3 Million Initial Financing and Technology License (findarticles.com) [edit]
  23. BrainCells raises $30M (venturebeat.com) [edit]
  24. Sequoia Pharmaceuticals Raises $35M In Series C Financing (fiercebiotech.com) [edit]
  25. VaxInnate Secures $40 Million Series C Financing. (thefreelibrary.com) [edit]
  26. VLST Corporation Raises $55 Million (vlstcorp.com) [edit]
  27. AVIDIA RAISES $43.8 MILLION TO ADVANCE NEW CLASS OF PHARMACEUTICALS (freshnews.com) [edit]
  28. AVIDIA ADVANCING LEAD PRODUCT THROUGH $28.5M SERIES B ROUND. (thefreelibrary.com) [edit]
  29. Company Overview (agtc.com) [edit]
Edit This Page
Last Edited 2/25/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy